cancer Despite considerable progress achieved in the last two decades in clinical oncology, metastatic breast carcinoma (MBC) still remains a fatal illness. Results of palliative polychemotherapy for MBC are still considered largely unsatisfactory 'Henderson, 1987) , but their translation to an adjuvant setting has led to important advances in the treatment of earlier stages (Henderson et al., 1988) .
Doxorubicin is commonly considered as the most active chemotherapeutic drug for the treatment of MBC, being able to induce a nearly 40% overall response rate when employed as a single agent (Hoogstraten, 1975) . The doxorubicin 4'-epimer epirubicin (EPI) has a more favourable therapeutic index than doxorubicin, since at equimolar doses it shows identical clinical activity with less haematological and cardiac toxicity (French Epirubicin Study Group, 1988; Bonadonna et al., 1993) .
Several data from precinical studies have shown that anthracycline drugs display a steep dose-response curve (Razak et al., 1972; Frei and Cannellos, 1980) . Clinical studies on acute myeloid leukaemia and bone sarcomas have shown that higher doses of anthracyclines are associated with higher complete response rates and improved survival (Cortes et al., 1978; Yates et al., 1982) . Moreover, retrospective analyses of clinical trials employing the cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) regimens in MBC carried out independently by Hryniuk (1987) and Tannock et al. (1988) showed that an increased dose intensity is associated with a better response rate and an increased quality of life. These data have been partially confirmed, at least in terms of response rates, in several clinical investigations on MBC treated with EPI (Hortobagyi, 1990; French Epirubicin Study Group, 1991; Habeshaw et al., 1991; Marschner et al., 1994) . For these reasons new regimens containing high-dose EPI have been developed with the aim of improving clinical results with acceptable toxicity (Hortobagyi, 1990; Ferguson et al., 1993; Marschner et al., 1994) .
The combination of 5-fluorouracil (5-FU). cyclophosphamide (CTX) and EPI employed in a wide dose range. the so-called' FEC regimen, has been largely employed in the treatment of MBC (French Epirubicin Study Group, 1988 Group, , 1991 Italian Multicenter Breast Study with Epirubicin, 1988) . Hortobagyi (1990) (Allegra. 1991) . The combination of l-FA and 5-FU has also been tested in MBC patients, achieving response rates ranging from 17% to 48%, largely depending on the extent of pretreatment (Loprinnzi, 1989 al., 1989; Palmenr et al., 1991 : Parnes et al.. 1991 Gebbia et al.. 1992) . It has recently been reported that human recombinant granulocyte colony-stimulating factor (G-CSF) used subcutaneously is able to reduce the duration of severe leucopenia and the incidence of mucositis and febrile events commonly associated with intensive chemotherapy (Bronchud et al., 1989; Gebbia et al., 1993) . G-CSF allowed a timely readministration or even anticipation of subsequent cycles obtained an increase in dose intensity.
According to the above-reported rationale. we carried out a multicentre study with the combination of CTX. 5-FU/I-FA, and escalating doses of EPI with G-CSF support with the aims of increasing anthracycline dosage to a level at which dose-limiting toxicity could be identified, shortening the inter-cycle interval, and improving dose intensity, as well as determining the clinical efficacy and toxicity of such a regimen.
Patients and methods

Eligibiliti criteria
Since the aims of this study included both the identification of dose-limiting toxicity and the evaluation of clinical efficacy in terms of objective regression rate, response duration and patient survival, measurable disease out with radiotherapy fields according to the WHO criteria (Miller et al., 1981) and&or thrombocytopenia (PTL .120000cellsi1-') treatment was delayed until day 28. With the exception of alopecia and leucopenia. the occurrence of grade 4 toxicity of any kind led to patients' withdrawal from chemotherapy. Treatment was stopped if LVEF decreased by > 15% from basal level and or patients developed initial signs of cardiac failure. Once EPI level was defined. the dose level was maintained for the remainder of the trial.
The first response evaluation was performed after the third cycle: in the case of complete objective tumour regression or stabilisation patients received a total of six cycles; in the case of progressive disease patients were withdrawn and followed up. In the case of partial response patients were treated for up to eight cycles and then followed up.
Responses and toxicity Patients were evaluated for objective response after three cycles according to the WHO response critenra (Miller et al., 1981 Hryniuk (1987) and the Wilcoxon rank sum test was used to evaluate the differences in EPI dose intensity.
Resuts Patient population
The main clinical and demographic characteristics of enrolled patients are depicted in Table I . Briefly, between April 1992 Table H , it was possible to increase EPI dosage from the starting dose of 90 mg mI-2 given at the first cycle to the first step of lOO mg M-2 in 53 patients (87%). EPI dosage could not be increased because of prolonged grade 4 leucopenia with neutropenia in four patients, and because of > grade 2 thrombocytopenia in four other patients. Subsequently, EPI dosage was further increased to llOmgm-2 in 31 patients (51%), while it was left unchanged (100 mgm-2) or reduced (90 mggm-) in 22 patients because of the occurrrence of grade 4 leucopenia, > grade 2 thrombocytopenia, > grade 2 anaemia, grade 3 stomatitis or a combination of these toxicities. Eighteen patients (30%) reached the final step of 120 mgm-2. In 13 patients EPI was not increased to 120 mg M-2 because of grade 4 leucopenia (three patients), thrombocytopenia > grade 2 (three patients), or prolonged grade 3 stomatitis (two patients). Dose escalation of EPI up to 120 mg m-2 was also not achievable in four patients who dropped out of the study because of progressive cancer. The differences between median WBC and ANC counts recorded at the four different levels of EPI were statistically significant (P = 0.006; P =0.005 respectively).
Moreover, a clear correlation was found between EPI dose anabsis considering all enroled patients (n = 64).
Among the 57 patints with metastatic disease there were 14 CR (25%) and 27 PR (47%) with an overall response rate (ORR) of 72% (95% CL 66-78%), while nine patients (16%) had stable disease, and four (7%) prog (three lost to follow-up). The median duration of CR and PR was 10 months and 13 months respectively. On (Henderson et al., 1988; Tannock et al., 1988; Hortobagyi, 1990; Marschner et al., 1994) . In fact, haematopoietic growth factors have been employed as rescue from myelosuppression with the aims of increasing the dose of antineoplastic drugs and also shortening the inter-cycle interval (Bronchud et al., 1989; O'Shaughness et al., 1990; Piccart, 1990; Ten Bokkel Huinink and Clavel, 1990; Habeshaw et al., 1991; Hoekman et al., 1991; Gebbia et al., 1994) . The ORR achieved in this multicentre study was 72% (95% CL 66-78%) with a 25% complete response rate. The median durations of complete and partial responses were 10 and 13 months respectively. The above-reported data confirm that this combination is active against MBC, achieving a high overall response rate similar to that reported with similar regimens (Hortobagyi, 1990; O'Shaughnessy et al., 1990) . Comparison of these results with those achieved by authors employing the same regimen with a lower dose of EPI, shows that higher doses of EPI may induce a 15% increase in ORR but a doubling in complete response rate (Palmeri et al., 1991) . However, it should be stressed that whether higher doses of EPI are associated with an increase in both rate and duration of objective response is beyond the aims of this study, and that this issue can be settled only in prospective randomised trials.
In conclusion, the DLT of EPI in combination with CTX and 3 day 5-FU/l-FA is represented by myelosuppression. These results further confirm that the use of G-CSF, given by a subcutaneous route, is effective in permitting an icreased EPI dosage in such a combination regimen above the conventional dose, up to 120mgm-2cycle-' in a significant percentage of patients. Intensive chemotherapy with G-CSF support may however sometimes result in very severe cumulative toxicity, which in the present study was represented by progressive anaemia and a trend towards PIFC and G-CSF in -nstacstdr brsmt canmw %9 G Coluca et at 1250 increasing thrombocytopenia. We feel that EPI 110mgm2 with G-CSF support can be employed in combination with CTX and 5-FU l-FA on an outpatient basis, but with a close follow-up. The combination of CTX. 5-FU/u-FA and highdose EPI with G-CSF support is highly effective against advanced breast cancer. However, this regimen cannot be recommended as routine standard therapy for metastatic breast cancer due to its significant toxicity and high cost, unless very aggressive and intensive chemotherapy is necssary.
